Alamar Biosciences

Alamar Biosciences is a proteomics company developing NULISA, a high-sensitivity proteomic platform that detects and quantifies protein biomarkers for early disease detection, alongside the automated ARGO high-throughput system. The company sells instruments, consumables, and services to global research institutions, biopharmaceutical companies, and contract research organizations across immunology, neurology, and oncology applications. Alamar completed its initial public offering in April 2026 and reported Q2 2026 revenue growth of 82% year over year, with gross margin expansion driven by consumables adoption.